The aim of the study was the estimation of practical benefit for the assessment of putative biomarkers of the detrusor overactivity (DO) in the blood and urine of patients together with other diagnostic modalities. Twenty patients with voiding dysfunction in age 28 to 60 years were included in the study. Control group consisted of 20 healthy patients (age 2072 years). In every patient the following biomarkers were measured quantitatively in the blood and urine: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor, VEGF), cortisol, granulocyte colony-stimulating factor (GCSF). Sonography of urinary tract with estimation of residual volume, urodynamics and urethrocystoscopy with a forceps biopsy of bladder wall were although carried out. Histological and immune-histochemical investigation of bioptates (including NGFR mousederived monoclonal antibodies) was performed. Increased levels of NGF, VEGF and GCSF in urine, and NGF, BDNF and GCSF in blood were detected in patients with multiple sclerosis (MS), compared to control group. There was no correlation between the levels of biomarkers in blood and in urine and severity of voiding dysfunction or urodynamic findings. NGFR was overexpressed in urothelium of patients with MS. It was shown for a first time, that urinary GCSF could be a biomarker of neurogenic detrusor overactivity.